Try our mobile app

Published: 2021-02-25 06:26:06 ET
<<<  go to SPNS company page
EX-99.1 2 ea136384ex99-1_sapiensinter.htm PRESS RELEASE

Exhibit 99.1

 

 

 

Sapiens Reports Q4 and Full Year 2020 Financial Results

 

Holon, Israel, February 25, 2021Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, and a member of the Formula Group (NASDAQ: FORTY and TASE: FORT), today announced its financial results for the fourth quarter and full year ended December 31, 2020.

 

Summary Results for Fourth Quarter 2020 (USD in millions, except per share data)

 

   GAAP           Non-GAAP     
   Q4 2020   Q4 2019   % Change       Q4 2020   Q4 2019   % Change 
Revenue  $101.7   $86.7    17.2%      $102.9   $86.7    18.7%
Gross Profit  $41.4   $34.9    18.4%      $47.0   $38.4    22.5%
Gross Margin   40.7%   40.3%   40 bps        45.7%   44.3%   140 bps 
Operating Income  $10.2   $10.2    -       $18.7   $14.3    30.1%
Operating Margin   10.1%   11.8%   (170) bps        18.1%   16.5%   160 bps 
Net Income (*)  $8.3   $6.8    21.7%      $14.5   $10.6    37.0%
Diluted EPS  $0.15   $0.13    15.4%      $0.27   $0.21    28.6%

 

Summary Results for Full Year 2020 (USD in millions, except per share data)

 

    GAAP               Non-GAAP        
    2020     2019     % Change         2020     2019     % Change  
Revenue   $ 382.9     $ 325.7       17.6 %       $ 384.5     $ 325.7       18.1 %
Gross Profit   $ 156.0     $ 129.5       20.4 %       $ 172.9     $ 143.0       20.9 %
Gross Margin     40.7 %     39.8 %     90 bps           45.0 %     43.9 %     110 bps  
Operating Income   $ 45.0     $ 37.9       18.8 %       $ 67.9     $ 52.2       30.1 %
Operating Margin     11.8 %     11.6 %     20 bps           17.7 %     16.0 %     170 bps  
Net income (*)   $ 33.8     $ 26.2       28.7 %       $ 52.0     $ 38.9       33.6 %
Diluted EPS   $ 0.65     $ 0.52       25.0 %       $ 1.00     $ 0.77       29.9 %

 

(*)Attributable to Sapiens’ shareholders.

 

1

 

 

“The non-GAAP financial results Sapiens reported today demonstrate how well we are executing our strategy. Sapiens ended the year on a strong note with record fourth quarter revenue and a strong operating margin. Despite COVID-19, we crossed the $100 million-dollar-mark in quarterly Non-GAAP revenues, coming in at $103 million, 19% higher than last year. Non-GAAP Operating margin was 18.1%, 164 basis points, or 29% improvement from fourth quarter 2019, validating our operating leverage. For the full year, 2020 NON-GAAP revenue increased by 18% to $384 million and we delivered NON-GAAP operating margin of 17.7%. The global Sapiens team executed extremely well in 2020, and I want to thank everyone for their outstanding work in a year that presented unique challenges and required tremendous adaptability,” stated Roni Al-Dor, President and CEO of Sapiens.

 

“We have proven repeatedly that our “Land and Expand” strategy is an efficient and effective way to grow in the highly regulated and regionally diverse global insurance markets. In addition to our global advantage, we offer customers a one-stop-shop in P&C and Life, along with complimentary and digital solutions. With hundreds of customers around the world, Sapiens is making a significant impact with our broad portfolio of solutions and one-hand-to-shake business model. We entered 2021 with a positive momentum and are planning to leverage our recent acquisitions,” continued Mr. Al-Dor. Mr. Al-Dor concluded: “We are introducing 2021 guidance for NON-GAAP revenue in a range of $457 million to $463 million, and NON-GAAP operating margin in a range of 17.7% to 18.0%, reflecting the likelihood that certain cost savings related to COVID-19 diminish in the second half of 2021. With a focused growth strategy, global diversity and an even stronger balance sheet, Sapiens is well positioned for success and growth.”

 

 

Quarterly Results Conference Call

Management will host a conference call and webcast today, February 25, 2021 at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results.

 

Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

North America (toll-free): + 1-888- 642-5032; International: +972-3-918-0609; UK: 0-800-917-5108

 

The live webcast of the call can be viewed on Sapiens’ website at: https://www.sapiens.com/investor-relations/ir-events-presentations.

 

If you are unable to join live, a replay of the call will be accessible until March 4, 2020, as follows:

North America: +1-877-456-0009; International: +972-3-925-5900.

 

A recorded version of the webcast will also be available via the Sapiens website, for three months at the same location.

 

2

 

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP operating income, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Adjusted EBITDA as net profit, adjusted for valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalized of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of  future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

3

 

 

About Sapiens

 

Sapiens International Corporation empowers insurers to succeed in an evolving industry. The company offers digital software platforms, solutions and services for the property and casualty, life, pension and annuity, reinsurance, financial and compliance, workers’ compensation and financial markets. With more than 35 years of experience delivering to more than 600 organizations globally, Sapiens has a proven ability to satisfy customers’ core, data and digital requirements. For more information: www.sapiens.com.

 

Forward Looking Statements

 

Certain matters discussed in this prospectus supplement, the accompanying prospectus and the other documents we have filed with the SEC that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the COVID-19 (coronavirus) pandemic, which may last longer than expected and materially adversely affect our results of operations; the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus outbreak, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.

 

While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in this prospectus supplement and in the accompanying prospectus, and under the heading “Risk Factors” in our most recent Annual Report on Form 20-F and in our other filings with the SEC that are incorporated by reference in this prospectus supplement and the accompanying prospectus, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus supplement, to conform these statements to actual results or to changes in our expectations.

 

Investors and Media Contact

Sapiens

Daphna Golden

Vice President, Head of Investor Relations

Email: ir@sapiens.com

 

Hayden IR
Brett Mass
Managing Partner
Phone: +1 646-536-7331
Email: Brett.Masss@HaydenIR.com

 

4

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

  

Three months ended

December 31

  

Year ended

December 31,

 
   2020   2019   2020   2019 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
Revenue   101,661    86,715    382,903    325,674 
Cost of revenue   60,288    51,782    226,929    196,153 
                     
Gross profit   41,373    34,933    155,974    129,521 
                     
Operating expenses:                    
Research and development, net   11,129    10,233    41,358    37,378 
Selling, marketing, general and administrative   20,019    14,477    69,613    54,274 
Total operating expenses   31,148    24,710    110,971    91,652 
                     
Operating income   10,225    10,223    45,003    37,869 
                    
Financial and other expenses, net   1,212    1,019    3,805    2,768 
Taxes on income   611    2,260    7,041    8,610 
                     
Net income   8,402    6,944    34,157    26,491 
                     
Attributable to non-controlling interest   83    110    382    244 
                     
Net income attributable to Sapiens’ shareholders   8,319    6,834    33,775    26,247 
                     
Basic earnings per share   0.16    0.14    0.67    0.53 
                     
Diluted earnings per share   0.15    0.13    0.65    0.52 
                     
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)   53,715    50,109    51,208    50,031 
                     
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)   54,541    51,009    52,159    50,653 

 

5

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED NON-GAAP STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

   Three months ended   Year ended  
   December 31   December 31, 
   2020   2019   2020   2019 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
Revenue   102,936    86,715    384,501    325,674 
Cost of revenue   55,892    48,313    211,560    182,662 
                     
Gross profit   47,044    38,402    172,941    143,012 
                     
Operating expenses:                    
Research and development, net   12,733    11,395    47,156    43,043 
Selling, marketing, general and administrative   15,645    12,662    57,863    47,763 
Total operating expenses   28,378    24,057    105,019    90,806 
                     
Operating income   18,666    14,345    67,922    52,206 
                     
Financial and other expenses, net   1,212    1,019    3,805    2,768 
Taxes on income   2,910    2,663    11,776    10,298 
                     
Net income   14,544    10,663    52,341    39,140 
                     
Attributable to non-controlling interest   83    110    382    244 
                     
Net income attributable to Sapiens’ shareholders   14,461    10,553    51,959    38,896 
                     
Basic earnings per share   0.27    0.21    1.01    0.78 
                     
Diluted earnings per share   0.27    0.21    1.00    0.77 
                     
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)   53,715    50,109    51,208    50,031 
                     
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)   54,541    51,009    52,159    50,653 

 

6

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

   Three months ended   Year ended 
   December 31,   December 31, 
   2020   2019   2020   2019 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
GAAP revenue   101,661    86,715    382,903    325,674 
Valuation adjustment on acquired deferred revenue   1,275    -    1,598    - 
Non-GAAP revenue   102,936    86,715    384,501    325,674 
                     
GAAP gross profit   41,373    34,933    155,974    129,521 
Revenue adjustment   1,275    -    1,598    - 
Amortization of capitalized software   1,931    1,499    6,558    5,668 
Amortization of other intangible assets   2,465    1,970    8,811    7,823 
Non-GAAP gross profit   47,044    38,402    172,941    143,012 
                     
GAAP operating income   10,225    10,223    45,003    37,869 
Gross profit adjustments   5,671    3,469    16,967    13,491 
Capitalization of software development   (1,604)   (1,162)   (5,798)   (5,665)
Amortization of other intangible assets   1,204    563    3,316    2,177 
Stock-based compensation   1,240    282    3,987    1,405 
Acquisition-related costs *)   1,930    970    4,447    2,929 
Non-GAAP operating income   18,666    14,345    67,922    52,206 
                     
GAAP net income attributable to Sapiens’ shareholders   8,319    6,834    33,775    26,247 
Operating income adjustments   8,441    4,122    22,919    14,337 
Taxes on income   (2,299)   (403)   (4,735)   (1,688)
Non-GAAP net income attributable to Sapiens’ shareholders   14,461    10,553    51,959    38,896 

 

(*)Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

7

 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

   Q4 2020   Q3 2020   Q2 2020   Q1 2020   Q4 2019 
                     
Revenues   102,936    97,968    93,063    90,534    86,715 
Gross profit   47,044    44,206    41,900    39,791    38,402 
Operating income   18,666    17,859    16,783    14,614    14,345 
Net income to Sapiens’ shareholders   14,461    13,746    13,340    10,412    10,553 
Adjusted EBITDA   20,032    19,010    17,854    15,724    15,271 
                          
Basic earnings per share   0.27    0.27    0.27    0.21    0.21 
Diluted earnings per share   0.27    0.27    0.26    0.20    0.21 

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

   Q4 2020   Q3 2020   Q2 2020   Q1 2020   Q4 2019 
                     
North America   47,303    49,979    46,610    44,567    41,787 
Europe   49,225    42,394    41,030    40,232    37,504 
Rest of the world   6,408    5,595    5,423    5,735    7,424 
                          
Total   102,936    97,968    93,063    90,534    86,715 

 

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

   Q4 2020   Q3 2020   Q2 2020   Q1 2020   Q4 2019 
                     
Cash-flow from operating activities   21,030    16,705    14,761    5,759    21,429 
Increase in capitalized software development costs   (1,604)   (1,506)   (1,251)   (1,437)   (1,162)
Capital expenditures   (725)   (963)   (393)   (552)   (2,456)
Free cash-flow   18,701    14,236    13,117    3,770    17,811 
                          
Cash payments attributed to acquisition-related
costs(*) (**)
   2,363    242    1,562    737    200 
                          
Adjusted free cash-flow   21,064    14,478    14,679    4,507    18,011 

 

(*)Included in cash-flow from operating activities

 

(**)Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.


 

8

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

   Three months ended   Year ended 
   December 31,   December 31, 
   2020   2019   2020   2019 
                 
GAAP operating profit   10,225    10,223    45,003    37,869 
                     
Non-GAAP adjustments:                    
Valuation adjustment on acquired deferred revenue   1,275    -    1,598    - 
Amortization of capitalized software   1,931    1,499    6,558    5,668 
Amortization of other intangible assets   3,669    2,533    12,127    10,000 
Capitalization of software development   (1,604)   (1,162)   (5,798)   (5,665)
Stock-based compensation   1,240    282    3,987    1,405 
Compensation related to acquisition and acquisition-related costs   1,930    970    4,447    2,929 
                     
Non-GAAP operating profit   18,666    14,345    67,922    52,206 
                     
Depreciation   1,366    926    4,698    3,470 
                     
Adjusted EBITDA   20,032    15,271    72,620    55,676 

 

9

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

 

   December 31,   December 31, 
   2020   2019 
   (unaudited)   (unaudited) 
         
ASSETS        
         
CURRENT ASSETS        
Cash and cash equivalents   152,561    66,295 
Short-term bank deposit   30,000    - 
Trade receivables, net and unbilled receivables   65,409    50,221 
Investment in restricted deposit   -    22,890 
Other receivables and prepaid expenses   19,388    7,817 
           
Total current assets   267,358    147,223 
           
LONG-TERM ASSETS          
Property and equipment, net   16,970    16,601 
Severance pay fund   6,582    5,106 
Goodwill and intangible assets, net   363,597    228,691 
Operating lease right-of-use assets   54,390    49,539 
Other long-term assets   5,264    5,261 
           
Total long-term assets   446,803    305,198 
           
TOTAL ASSETS   714,161    452,421 
           
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES          
Trade payables   5,389    5,107 
Current maturities of Series B Debentures   19,796    9,898 
Accrued expenses and other liabilities   75,119    60,574 
Current maturities of operating lease liabilities   9,924    8,312 
Deferred revenue   34,548    21,021 
           
Total current liabilities   144,776    104,912 
           
LONG-TERM LIABILITIES          
Series B Debentures, net of current maturities   98,676    58,850 
Deferred tax liabilities   16,010    5,082 
Other long-term liabilities   12,129    8,321 
Long-term operating lease liabilities   48,773    43,394 
Accrued severance pay   9,586    6,364 
           
Total long-term liabilities   185,174    122,011 
           
REDEEMABLE NON-CONTROLLING INTEREST   517    - 
           
EQUITY   383,694    225,498 
           
TOTAL LIABILITIES AND EQUITY   714,161    452,421 

 

10

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

    For the twelve months ended December 31,  
    2020     2019  
    (unaudited)     (unaudited)  
Cash flows from operating activities:            
Net income     34,157       26,491  
Reconciliation of net income to net cash provided by operating activities:                
Impairment of right of use asset     351       -  
Depreciation and amortization     23,383       19,138  
Accretion of discount on Series B Debentures     134       171  
Capital loss (gain) from sale of property and equipment     44       (40 )
Stock-based compensation related to options issued to employees     3,987       1,405  
                 
Net changes in operating assets and liabilities, net of amount acquired:                
Trade receivables, net and unbilled receivables     (5,168 )     10,514  
Deferred tax assets, net     (16 )     (6,441 )
Other operating assets     (2,049 )     6,726  
Trade payables     (1,344 )     (1,476 )
Other operating liabilities     1,435       6,667  
Deferred revenues     2,992       2,747  
Accrued severance pay, net     349       255  
                 
Net cash provided by operating activities     58,255       66,157  
                 
Cash flows from investing activities:                
Purchase of property and equipment     (2,633 )     (11,474 )
Investment in deposit     (30,397 )     (1,119 )
Proceeds from sale of property and equipment     12       834  
Proceeds from (investment in) restricted deposit used for completed acquisition     22,890       (22,890 )
Payments for business acquisitions, net of cash acquired     (95,866 )     (1,554 )
Capitalized software development costs     (5,798 )     (5,665 )
Acquisition of intellectual property     (2,810 )     -  
                 
Net cash used in investing activities     (114,602 )     (41,868 )
                 
Cash flows from financing activities:                
Proceeds from employee stock options exercised     5,050       780  
Distribution of dividend     (7,044 )     (11,009 )
Repayment of Series B Debenture     (9,898 )     (9,898 )
Proceeds from issuance of Series B Debentures     60,346       -  
Receipt of short-term loan     20,000       -  
Repayment of loan     (20,000 )     (4 )
Payment of contingent considerations     (538 )     (374 )
Acquisition of minority interests     (147 )     -  
Dividend to non-controlling interest     -       (149 )
Repayment of loan of acquired subsidiary     (13,186 )     -  
Proceeds from issuance of ordinary shares, net of issuance expenses     108,737       -  
                 
Net cash provided by (used in) financing activities     143,320       (20,654 )
                 
Effect of exchange rate changes on cash and cash equivalents     (707 )     (1,968 )
                 
Increase in cash and cash equivalents     86,266       1,667  
Cash and cash equivalents at the beginning of period     66,295       64,628  
                 
Cash and cash equivalents at the end of period     152,561       66,295  

 

11

 

  

Debentures Covenants

 

As of December 31, 2020, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

Target shareholders’ equity (excluding minority interest): above $120 million.
   
Actual shareholders’ equity (excluding minority interest) equal to $382 million.

 

Covenant 2

 

Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.
   
 Actual ratio of net financial indebtedness to net capitalization equal to (9.75)%.
   

Covenant 3

 

Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
   
Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (0.47).

 

 

12